News

Ten-year trial shows CD22 CAR T drives deep remissions in relapsed pediatric B-ALL, with transplant boosting durability and manageable toxicity.

Phase 1 data show HER2 ADC trastuzumab rezetecan drives responses in advanced gastric/GEJ and colorectal cancers with manageable safety and low ILD.

The combination of selinexor and ruxolitinib achieved a statistically significant and sustained reduction in spleen volume compared with ruxolitinib alone in patients with JAK inhibitor treatment-naïve myelofibrosis, though symptom improvement was comparable across both arms.

Most patients with heavily pretreated chronic GVHD experienced clinical benefit with axatilimab, with the majority continuing treatment after approval.

Phase 3 data show oral sunvozertinib beats platinum chemo in EGFR exon 20ins NSCLC, boosting PFS and responses with tolerable safety.

ELCC 2026 spotlights lung cancer breakthroughs—ADCs, EGFR combo sequencing, HER2 TKIs and SCLC bispecifics—reshaping treatment choices.

During a live event, the benefit of adding nivolumab (Opdivo) to tivozanib (Fotivda) in the second-line setting was discussed by David Braun, MD, and participants.

Post-transplant gilteritinib maintenance may boost survival and reduce relapse in relapsed FLT3-mutated AML, though larger trials are still needed.

Phase 3 results show that fecal microbiotherapy achieved a 62% GI response rate and a 54% 1-year survival in patients who had failed both corticosteroids and ruxolitinib.

Positive efficacy signals in progression-free survival (PFS) and objective response rate (ORR) did not translate into an overall survival (OS) benefit for first-line lenvatinib (Lenvima) plus pembrolizumab (Keytruda) in patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).

Real-world brexu-cel CAR-T data in adult R/R B-ALL show trial-like ICANS, CRS, and highlight monitoring and risk factors.

FDA approves nivolumab with AVD for Hodgkin lymphoma, showing superior survival rates and reduced toxicity compared to existing treatments.

Phase 2 data show one-time liso-cel CAR T delivers 95% responses in hard-to-treat marginal zone lymphoma, with low severe CRS and neurotoxicity.

Nadofaragene firadenovec-vncg (Adstiladrin) received an expanded NCCN recommendation for patients with BCG-unresponsive NMIBC.

In patients with high-grade uterine sarcoma who achieved disease control, cabozantinib did not prolong survival and had added toxicity.

Genomic assays guide adjuvant therapy in HR-positive, HER2-negative breast cancer, clarifying who benefits from chemo by age, nodal status, and risk score.

FDA grants orphan drug status to irinotecan ChemoSeed implant for high-grade gliomas, enabling sustained local brain tumor therapy and accelerating pivotal trials.

Early results from TALAPRO-3 suggest that the combination of talazoparib and enzalutamide may redefine the treatment paradigm for HRR gene-mutated mCSPC, demonstrating that targeting DNA damage repair earlier in the disease course substantially delays radiographic progression.

FDA clears teclistamab plus daratumumab for early-relapse multiple myeloma, delivering striking PFS gains and scalable outpatient use.

Talquetamab delivers high response rates in refractory myeloma; learn how to prevent skin, nail and oral side effects to stay on therapy.

During a live event, Catherine Coombs, MD and participants debate frontline CLL BTK inhibitors: who benefits from continuous therapy, acalabrutinib vs zanubrutinib nuances, and pirtobrutinib's future role.

FDA clears MyChoice CDx to find HRD-positive advanced ovarian cancer patients for niraparib, using BRCA and genomic instability testing.

The combination of nogapendekin alfa inbakicept-pmln (Anktiva) and Bacillus Calmette-Guérin was added to the NCCN clinical guidelines for bladder cancer, according to the manufacturer.

Aglatimagene besadenovec intratumoral gene therapy plus valacyclovir shows durable survival in ICI-resistant advanced NSCLC, fueling pivotal phase 3 plans.

Three-year follow-up data from the phase 3 RATIONALE-309 trial show that tislelizumab plus chemotherapy provides durable progression-free survival and a clinically meaningful overall survival advantage over placebo in recurrent or metastatic nasopharyngeal carcinoma.

A single-arm study of a BCMA CAR T-cell therapy after induction for newly diagnosed multiple myeloma led to 100% minimal residual disease negativity at 3 months.

Deepak Kilari, MD, shared his insights on recent trials in renal cell carcinoma presented at the 2026 ASCO Genitourinary Cancers Symposium.

COMPASSION-03 follow-up shows cadonilimab delivers durable survival in recurrent/metastatic cervical cancer, including PD‑L1–negative patients.